Acumen Pharma to Present Insights from Phase 1 INTERCEPT-AD Study at AAIC 2024

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company located in Newton, Mass., has announced it will present new data from its Phase 1 INTERCEPT-AD study of sabirnetug (ACU193) at the Alzheimer’s Association International Conference (AAIC®) 2024. Scheduled in Philadelphia and online from July 28 to August 1, 2024, the presentations will focus on patient experiences and biomarker data related to sabirnetug, a novel therapeutic targeting toxic soluble amyloid beta oligomers (AβOs) for Alzheimer's disease (AD).

Sabirnetug is notable for being the first humanized monoclonal antibody to selectively target AβOs in patients with early symptomatic AD. These oligomers are a highly toxic and soluble form of amyloid beta that contributes to synaptic dysfunction and neurodegeneration in Alzheimer's. By focusing on AβOs, sabirnetug aims to offer a potentially superior treatment option for early symptomatic AD.

Key details about Acumen’s presentations include:

Sunday, July 28:
- Session: Public Health Epidemiology (7:30 a.m.-4:15 p.m.); Pennsylvania Convention Center
- Poster #684: Discusses gender analysis in the Phase 1 trial among early AD patients and their study partners.
- Session: Developing Topics: Drug Development (8:00 a.m.-4:15 p.m.); Pennsylvania Convention Center
- Poster #826: Covers the development and validation of a sensitive immunoassay to detect total sabirnetug levels in human cerebrospinal fluid (CSF).

Monday, July 29:
- Session: Developing Topics: Biomarkers (8:00 a.m.-4:15 p.m.); Pennsylvania Convention Center
- Poster #785: Provides an analysis of CSF levels of synaptic biomarkers associated with sabirnetug in the Phase 1 study.

Wednesday, July 31:
- Session: Dementia Care Research and Psychosocial Factors (7:30 a.m.-4:15 p.m.)
- Poster #637: Examines patient experiences and expectations for treatment through qualitative interviews with early AD trial participants and their partners.

Acumen’s team members will also be available at booth #1137 in the Exhibit Hall to discuss their program and potential collaborative opportunities.

Sabirnetug (ACU193): A Promising Treatment for Early Alzheimer’s

Sabirnetug (ACU193) is a humanized monoclonal antibody developed for its selectivity towards soluble amyloid beta oligomers (AβOs). These oligomers are a toxic and pathogenic form of amyloid beta, different from the more studied amyloid plaques and monomers. AβOs are potent neurotoxins that bind to neurons, disrupting synaptic function and inducing neurodegeneration. By specifically targeting these toxic oligomers, sabirnetug aims to address a key underlying cause of neurodegeneration in Alzheimer’s disease.

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to sabirnetug for the treatment of early AD. The Phase 1 INTERCEPT-AD trial, completed in 2023, was a U.S.-based, multi-center, randomized, double-blind, placebo-controlled study. It evaluated the safety and tolerability of sabirnetug, enrolling 65 participants with early AD. The trial consisted of single and multiple ascending dose cohorts to assess the drug's safety, pharmacokinetics, and target engagement.

About Acumen Pharmaceuticals

Acumen Pharmaceuticals is committed to developing innovative treatments targeting toxic soluble amyloid beta oligomers (AβOs) for Alzheimer’s disease. Founded on pioneering research, Acumen is advancing its lead product candidate, sabirnetug (ACU193), through clinical trials. Following positive results from its Phase 1 INTERCEPT-AD study, Acumen is now conducting a Phase 2 trial, ALTITUDE-AD, to further evaluate sabirnetug in patients with early symptomatic Alzheimer’s disease. The company is headquartered in Newton, Mass.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!